GW Pharmaceuticals: Best Cannabis Play And A Renewed Buy After Q4 Results

Summary

Leading player in the medical marijuana space, has world trends on its side, and is well financed.

Ramping up manufacturing facilities for its new "Epidiolex" drug.

Multiple cannabinoid programs in the testing pipeline for 2016.

Q4 results close to analyst expectations, but cash reserves more important than profitability at this time.

Possible takeover target for Big Pharma.

 

Overview

In my article in October, I detailed how world trends are favorable to the medical marijuana space. Since then, there have been significant developments on several fronts, both in general and specifically for GW Pharmaceuticals (NASDAQ:GWPH). These crucial new company developments were detailed at the Q4 results briefing.

There is a growing acceptance worldwide of cannabis. This was strengthened by the recent election victory in Canada by a party promising to legalize recreational cannabis. Already in Canada medical marijuana...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.